Paul R. Edick - 27 Oct 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Reporting relationship: Director
Issuer ticker: VTGN
Reported as of: 27 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2025, 16:34:49 UTC
Prior SEC filing: 31 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Paul R. Edick

Key filing fact

Paul R. Edick filed Form 4 for Vistagen Therapeutics, Inc. (VTGN) on 04 Nov 2025.

Key facts

This page summarizes Paul R. Edick's Form 4 filing for Vistagen Therapeutics, Inc. (VTGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2025, 16:34.

Change

Previous filing in this sequence was filed on 31 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001531178 Primary reporting owner

Edick Paul R

Relationship: Director
Address: C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Signature: /s/ Paul R. Edick
Signature date: 04 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +35,200
Change %
Price
Shares after: 35,200
Date: 27 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,200
Exercise price: $3.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant.